Baker BROS. Advisors LP Has $5.38 Million Holdings in Fate Therapeutics, Inc. (NASDAQ:FATE)

Baker BROS. Advisors LP grew its position in Fate Therapeutics, Inc. (NASDAQ:FATE - Free Report) by 8.7% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 3,258,402 shares of the biopharmaceutical company's stock after purchasing an additional 260,630 shares during the quarter. Baker BROS. Advisors LP owned about 2.86% of Fate Therapeutics worth $5,376,000 as of its most recent SEC filing.

A number of other large investors also recently made changes to their positions in FATE. China Universal Asset Management Co. Ltd. bought a new position in shares of Fate Therapeutics during the fourth quarter worth approximately $40,000. FPC Investment Advisory Inc. bought a new position in Fate Therapeutics during the 4th quarter worth $44,000. Y Intercept Hong Kong Ltd acquired a new position in Fate Therapeutics in the 4th quarter valued at $58,000. Intech Investment Management LLC lifted its position in shares of Fate Therapeutics by 27.5% during the 4th quarter. Intech Investment Management LLC now owns 39,443 shares of the biopharmaceutical company's stock valued at $65,000 after acquiring an additional 8,497 shares during the period. Finally, SG Americas Securities LLC increased its position in shares of Fate Therapeutics by 30.6% in the fourth quarter. SG Americas Securities LLC now owns 44,874 shares of the biopharmaceutical company's stock worth $74,000 after purchasing an additional 10,511 shares during the period. Institutional investors own 97.54% of the company's stock.

Wall Street Analysts Forecast Growth

FATE has been the subject of several recent analyst reports. Needham & Company LLC reaffirmed a "hold" rating on shares of Fate Therapeutics in a research report on Thursday, March 6th. Stifel Nicolaus decreased their price objective on shares of Fate Therapeutics from $5.00 to $3.00 and set a "hold" rating on the stock in a research note on Thursday, March 6th. Wedbush restated a "neutral" rating and set a $5.00 target price on shares of Fate Therapeutics in a research note on Thursday, March 6th. Wells Fargo & Company decreased their price target on Fate Therapeutics from $5.00 to $4.00 and set an "equal weight" rating on the stock in a research note on Thursday, March 6th. Finally, StockNews.com downgraded Fate Therapeutics from a "hold" rating to a "sell" rating in a research report on Tuesday, March 11th. One analyst has rated the stock with a sell rating, seven have assigned a hold rating and two have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the stock has an average rating of "Hold" and an average target price of $5.43.

Fate Therapeutics Stock Down 18.5 %

Shares of FATE stock traded down $0.22 during mid-day trading on Tuesday, reaching $0.95. 3,971,111 shares of the stock traded hands, compared to its average volume of 2,276,050. The company has a market cap of $109.22 million, a price-to-earnings ratio of -0.58 and a beta of 2.31. The stock's fifty day simple moving average is $1.01 and its two-hundred day simple moving average is $1.61. Fate Therapeutics, Inc. has a 1-year low of $0.66 and a 1-year high of $5.92.

Fate Therapeutics (NASDAQ:FATE - Get Free Report) last announced its quarterly earnings results on Wednesday, March 5th. The biopharmaceutical company reported ($0.31) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.44) by $0.13. The firm had revenue of $1.86 million during the quarter, compared to analysts' expectations of $1.57 million. Fate Therapeutics had a negative net margin of 1,325.43% and a negative return on equity of 45.88%. On average, equities research analysts anticipate that Fate Therapeutics, Inc. will post -1.63 EPS for the current fiscal year.

Fate Therapeutics Profile

Fate Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders.